Related Experiment Video
Updated: Jun 30, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European
J H J M van Krieken1, A Jung, T Kirchner
1Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500, HB, The Netherlands. J.vanKrieken@pathol.umcn.nl
Abstract:
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
Insights
KRAS mutation testing is crucial for predicting colorectal cancer patient response to epidermal growth factor receptor (EGFR) therapies. Standardized testing is needed to ensure accurate results and optimize treatment selection.
Area of Science:
- Oncology
- Molecular Diagnostics
- Pharmacogenomics
Background:
- Epidermal growth factor receptor (EGFR) inhibitors have improved outcomes for colorectal carcinoma patients.
- Treatment efficacy is limited to a subset of patients, often due to KRAS gene mutations.
- KRAS mutations (30-40% of colorectal tumors) predict poor response to anti-EGFR therapies.
Purpose of the Study:
- To review the molecular basis of EGFR-targeted therapies and KRAS-mediated resistance.
- To highlight the challenges posed by the lack of validated KRAS mutation analysis methods.
- To propose solutions for accurate and proficient KRAS testing in colorectal cancer management.
Main Methods:
- Literature review on EGFR-targeted therapies and KRAS mutation impact.
- Analysis of current diagnostic tools for KRAS mutation detection.
- Presentation of guideline recommendations and a quality assurance program proposal.
Main Results:
- KRAS mutation status is a key predictive biomarker for anti-EGFR therapy response in colorectal cancer.
- Current diagnostic landscape lacks standardized and validated methods for KRAS testing.
- A European quality assurance program is proposed to improve testing accuracy.
Conclusions:
- Accurate KRAS mutation testing is essential for personalized anti-EGFR therapy selection in colorectal carcinoma.
- Standardization and quality assurance are critical to overcome current diagnostic challenges.
- Implementation of a European quality assurance program could enhance patient outcomes.
